Global Lenvatinib Market Size, Share and Trends Analysis Report, By Application (Thyroid Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, and Endometrial Cancer), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast (2022-2028)

The lenvatinib market is anticipated to grow at a significant CAGR 5% during the forecast period (2022-2028). Lenvatinib is a medicine used in the treatment of symptoms of differentiated thyroid cancer, advanced renal cell carcinoma, hepatocellular carcinoma, and endometrial cancer. It can be used alone or in combination with other drugs. The major factors driving the growth of the market are the rising prevalence of cellular carcinoma and thyroid cancer. According to the American Society for Clinical Oncology, in 2022, an estimated 44,280 adults (12,150 men and 32,130 women) in the US will be diagnosed with thyroid cancer. Thyroid cancer is the seventh most common cancer in women. Similarly, according to the American Cancer Society, in 2022, around 79,000 new cases of kidney cancer (50,290 in men and 28,710 in women) will be diagnosed and around 13,920 people (8,960 men and 4,960 women) will die from this disease.

The global lenvatinib market is segmented based on application and distribution channels. Based on application, the market is sub-segmented into thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial cancer. Based on distribution channels, the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The market players are also contributing significantly to the market growth by adopting various strategies, including mergers, acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in February 2020, Shilpa Medicare Ltd. announced that the company had received regulatory approval to market a lenvatinib mesylate, a breakthrough therapy for the treatment of patients with differentiated thyroid cancer and hepatocellular carcinoma. Shilpa had received regulatory approval for Lenvatinib 4 mg and 10 mg capsules, after successfully showing bioequivalence to Lenvima, a brand of Lenvatinib mesylate capsules marketed by Eisai.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Merck & Co. Inc., Eisai Pharmaceuticals Co., Bayer AG, Teva Pharmaceutical Industries Ltd., Piramal Enterprises Ltd., Mankind Pharma Ltd., Lupin Ltd., and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lenvatinib Market Report by Segment

By Application

• Thyroid Cancer
• Renal Cell Carcinoma
• Hepatocellular Carcinoma
• Endometrial Cancer

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Lenvatinib Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa